These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 22373834)

  • 21. Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice.
    Bykerk VP; Östör AJ; Alvaro-Gracia J; Pavelka K; Román Ivorra JA; Graninger W; Bensen W; Nurmohamed MT; Krause A; Bernasconi C; Aassi M; Sibilia J
    Clin Rheumatol; 2015 Mar; 34(3):563-71. PubMed ID: 25604316
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interpreting the multi-biomarker disease activity score in the context of tocilizumab treatment for patients with rheumatoid arthritis.
    Reiss WG; Devenport JN; Low JM; Wu G; Sasso EH
    Rheumatol Int; 2016 Feb; 36(2):295-300. PubMed ID: 26026604
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lack of interaction between bromfenac and methotrexate in patients with rheumatoid arthritis.
    Gumbhir-Shah K; Cevallos WH; DeCleene SA; Korth-Bradley JM
    J Rheumatol; 1996 Jun; 23(6):984-9. PubMed ID: 8782127
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Accelerated subcutaneous nodulosis in patients with rheumatoid arthritis treated with tocilizumab: a case series.
    Talotta R; Atzeni F; Batticciotto A; Ditto MC; Gerardi MC; Sarzi-Puttini P
    J Med Case Rep; 2018 Jun; 12(1):154. PubMed ID: 29859543
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IL-6 receptor inhibition modulates type III collagen and C-reactive protein degradation in rheumatoid arthritis patients with an inadequate response to anti-tumour necrosis factor therapy: analysis of connective tissue turnover in the tocilizumab RADIATE study.
    Juhl P; Thudium CS; Gudmann NS; Karsdal MA; Bay-Jensen AC; Siebuhr AS
    Clin Exp Rheumatol; 2018; 36(4):568-574. PubMed ID: 29465346
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year.
    Kremer JM; Blanco R; Brzosko M; Burgos-Vargas R; Halland AM; Vernon E; Ambs P; Fleischmann R
    Arthritis Rheum; 2011 Mar; 63(3):609-21. PubMed ID: 21360490
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of tocilizumab on bone mineral density in patients with methotrexate-resistant active rheumatoid arthritis.
    Kume K; Amano K; Yamada S; Kanazawa T; Ohta H; Hatta K; Amano K; Kuwaba N
    Rheumatology (Oxford); 2014 May; 53(5):900-3. PubMed ID: 24441151
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of disease-drug-drug interaction between single-dose tocilizumab and oral contraceptives in women with active rheumatoid arthritis.
    Zhang X; Rowell L; Fettner S; Lau C; Teuber D
    Int J Clin Pharmacol Ther; 2014 Jan; 52(1):27-38. PubMed ID: 24161161
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patient-reported outcomes in newly diagnosed early rheumatoid arthritis patients treated to target with a tocilizumab- or methotrexate-based strategy.
    Teitsma XM; Jacobs JWG; Welsing PMJ; Pethö-Schramm A; Borm MEA; Hendriks L; Denissen NHAM; van Laar JM; Lafeber FPJG; Bijlsma JWJ
    Rheumatology (Oxford); 2017 Dec; 56(12):2179-2189. PubMed ID: 29029185
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the efficacies of abatacept and tocilizumab in patients with rheumatoid arthritis by propensity score matching.
    Kubo S; Nakayamada S; Nakano K; Hirata S; Fukuyo S; Miyagawa I; Hanami K; Saito K; Tanaka Y
    Ann Rheum Dis; 2016 Jul; 75(7):1321-7. PubMed ID: 26245754
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.
    Smolen JS; Beaulieu A; Rubbert-Roth A; Ramos-Remus C; Rovensky J; Alecock E; Woodworth T; Alten R;
    Lancet; 2008 Mar; 371(9617):987-97. PubMed ID: 18358926
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis.
    Gabay C; McInnes IB; Kavanaugh A; Tuckwell K; Klearman M; Pulley J; Sattar N
    Ann Rheum Dis; 2016 Oct; 75(10):1806-12. PubMed ID: 26613768
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response.
    Breedveld F; Agarwal S; Yin M; Ren S; Li NF; Shaw TM; Davies BE
    J Clin Pharmacol; 2007 Sep; 47(9):1119-28. PubMed ID: 17766699
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry.
    Leffers HC; Ostergaard M; Glintborg B; Krogh NS; Foged H; Tarp U; Lorenzen T; Hansen A; Hansen MS; Jacobsen MS; Dreyer L; Hetland ML;
    Ann Rheum Dis; 2011 Jul; 70(7):1216-22. PubMed ID: 21551512
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE study 2-year results.
    Fleischmann RM; Halland AM; Brzosko M; Burgos-Vargas R; Mela C; Vernon E; Kremer JM
    J Rheumatol; 2013 Feb; 40(2):113-26. PubMed ID: 23322466
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis.
    Soini EJ; Hallinen TA; Puolakka K; Vihervaara V; Kauppi MJ
    J Med Econ; 2012; 15(2):340-51. PubMed ID: 22168785
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Golimumab pharmacokinetics after repeated subcutaneous and intravenous administrations in patients with rheumatoid arthritis and the effect of concomitant methotrexate: an open-label, randomized study.
    Zhuang Y; Xu Z; Frederick B; de Vries DE; Ford JA; Keen M; Doyle MK; Petty KJ; Davis HM; Zhou H
    Clin Ther; 2012 Jan; 34(1):77-90. PubMed ID: 22169051
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravenous tocilizumab: a review of its use in adults with rheumatoid arthritis.
    Dhillon S
    BioDrugs; 2014 Feb; 28(1):75-106. PubMed ID: 24255004
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fostamatinib, a Syk-kinase inhibitor, does not affect methotrexate pharmacokinetics in patients with rheumatoid arthritis.
    Baluom M; Samara E; Grossbard EB; Lau DT
    J Clin Pharmacol; 2011 Sep; 51(9):1310-8. PubMed ID: 21209239
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study).
    Izumi K; Kaneko Y; Hashizume M; Yoshimoto K; Takeuchi T
    PLoS One; 2015; 10(12):e0145468. PubMed ID: 26698858
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.